TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23644651

Group type: EXPERIMENTAL
Intervention: Treadmill walking
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Elliptical training
Number of subjects: 16
Study: 20663996

Group type: EXPERIMENTAL
Intervention: Argatroban (250, 300, or 350 µg/kg as bolus before PCI, followed by 15, 20, or 25 µg/kg/min infusion)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Unfractionated heparin (70-100 IU/kg bolus)
Number of subjects: 140
Study: 19634959

Group type: EXPERIMENTAL
Intervention: Integrated, manualized intervention (individual counseling and peer group education/support)
Number of subjects: 253

Group type: COMPARATOR
Intervention: Control condition (resource referrals)
Number of subjects: 253
Study: 16717320

Group type: EXPERIMENTAL
Intervention: Acupuncture at special sedation points
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Laserneedle acupuncture at special sedation points
Number of subjects: 9

Group type: COMPARATOR
Intervention: Acupuncture of points for increasing 'Qi-energy'
Number of subjects: 9
Study: 14766713

Group type: EXPERIMENTAL
Intervention: Double setup ETT
Number of subjects: 200

Group type: COMPARATOR
Intervention: Single ETT
Number of subjects: 200
Study: 11868762

Group type: EXPERIMENTAL
Intervention: Linezolid 600 mg tablets b.i.d. for 7 d
Number of subjects: 12

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanic acid 1000 mg tablets o.d. for 7 d
Number of subjects: 12
Study: 12515162

Group type: EXPERIMENTAL
Intervention: L-HSA-Ara-AMP (35 mg/Kg daily for 5 days)
Number of subjects: 10
Study: 7989928

Group type: EXPERIMENTAL
Intervention: Preparatory regimen consisting of fractionated total-body irradiation (12 Gy total administered in 10 1.2-Gy fractions), etoposide (60 mg/kg), and cyclophosphamide (100 mg/kg).
Number of subjects: 96
Study: 2543553

Group type: EXPERIMENTAL
Intervention: Beet-fibre diet (mean 40 g FibrexR, 27 g dietary fibre per day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Beet-fibre diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 12
Study: 1123455

Group type: EXPERIMENTAL
Intervention: Betahistine hydrochloride (SERC), 20 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Betahistine hydrochloride (SERC), high dosage (16 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 31349865

Group type: EXPERIMENTAL
Intervention: Simplified‐PIL
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: No‐PIL
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard‐PIL
Number of subjects: 102
Study: 27714451

Group type: EXPERIMENTAL
Intervention: PSI with gap balancing (PSI-GB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: PSI with conventional technique (PSI-S)
Number of subjects: 50
Study: 26403410

Group type: EXPERIMENTAL
Intervention: Topical corticosteroids (methylprednisolone aceponat), applied once a day for three months (group A)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Topical calcineurin inhibitors (tacrolimus), applied twice a day for three months (group B)
Number of subjects: 45
Study: 23948642

Group type: EXPERIMENTAL
Intervention: Risk score based on clinical variables (age, residence, body mass index, on-treatment heart rate and BP, prior myocardial infarction, heart failure, stroke/transient ischemic attack, smoking, diabetes, peripheral arterial disease, chronic kidney disease)
Number of subjects: 18484

Group type: EXPERIMENTAL
Intervention: Risk score model
Number of subjects: 18484
Study: 21480317

Group type: EXPERIMENTAL
Intervention: Pegylated interferon and ribavirin therapy
Number of subjects: 871
Study: 19472884

Group type: EXPERIMENTAL
Intervention: Maxillary protraction with rapid palatal expansion (RPE)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Maxillary protraction without rapid palatal expansion (RPE)
Number of subjects: 31
Study: 16918513

Group type: EXPERIMENTAL
Intervention: VLA-4 antagonist GW559090X (3 mg)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) (500 microg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 15307010

Group type: EXPERIMENTAL
Intervention: 300 mg once-daily lamivudine (3TC)
Number of subjects: 554

Group type: COMPARATOR
Intervention: 150 mg twice-daily lamivudine (3TC)
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: 300 mg twice-daily zidovudine
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: 600 mg once-daily efavirenz
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Adverse events, disease progression, and HIV-associated conditions
Number of subjects: 554
Study: 11795863

Group type: EXPERIMENTAL
Intervention: H. pylori eradication therapy (triple-therapy: Clarithromycin, Amoxicillin, and Omeprazole for one week)
Number of subjects: 192

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: H. pylori positive patients (CagA positive)
Number of subjects: 192

Group type: COMPARATOR
Intervention: H. pylori negative patients
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: CagA positive H. pylori infection
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: H. pylori infection
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: CagA IgG detection
Number of subjects: 192

Group type: EXPERIMENTAL
Intervention: H. pylori DNA detection
Number of subjects: 192
Study: 9463301

Group type: EXPERIMENTAL
Intervention: New allopurinol formulation (300 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Reference allopurinol formulation
Number of subjects: 18
Study: 8431665

Group type: EXPERIMENTAL
Intervention: Enalapril (0.1 mg/kg)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 3038987

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (1% w/v)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 29461667

Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study: 26850803

Group type: EXPERIMENTAL
Intervention: Lavender essential oil inhalation (5% for 10 min, three times a week for 4 weeks)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 59
Study: 24225740

Group type: EXPERIMENTAL
Intervention: CYL concentrate supplementation group (CS group)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo group (PL group)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Antioxidant capsule group (AO group)
Number of subjects: 17
Study: 23768271

Group type: EXPERIMENTAL
Intervention: CV-4
Number of subjects: 10

Group type: COMPARATOR
Intervention: Sham-CV4
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control
Number of subjects: 10
Study: 20634268

Group type: EXPERIMENTAL
Intervention: Manipulation + exercise group
Number of subjects: 140

Group type: COMPARATOR
Intervention: Exercise-only group
Number of subjects: 140
Study: 18709511

Group type: EXPERIMENTAL
Intervention: Laparoscopic antireflux surgery (LARS)
Number of subjects: 554

Group type: COMPARATOR
Intervention: Esomeprazole (20-40 mg daily)
Number of subjects: 554
Study: 16793163

Group type: EXPERIMENTAL
Intervention: Information booklet (the 'back book') and usual physical therapy
Number of subjects: 142

Group type: COMPARATOR
Intervention: Usual physical therapy only with nonstandardized oral information
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Information booklet (the 'back book')
Number of subjects: 142
Study: 14738126

Group type: EXPERIMENTAL
Intervention: Lozenge containing 56.4mg (3 percent w/w) CPP-ACP
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lozenge containing 18.8mg (1 percent w/w) CPP-ACP
Number of subjects: 10

Group type: COMPARATOR
Intervention: Lozenge not containing CPP-ACP
Number of subjects: 10

Group type: COMPARATOR
Intervention: No lozenge nil-treatment control
Number of subjects: 10
Study: 10960928

Group type: EXPERIMENTAL
Intervention: Brief psychoeducational group program for partners
Number of subjects: 36
Study: 8636748

Group type: EXPERIMENTAL
Intervention: New York (NY) regimen
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Berlin-Frankfurt-Munster (BFM) regimen
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Day 7 marrow evaluation
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Day 14 marrow evaluation
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Day 7 marrow with WBC count > 200,000/microL
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Day 14 marrow evaluation for slow responders
Number of subjects: 220
Study: 7936829

Group type: EXPERIMENTAL
Intervention: 3-hydroxyacyl-CoA dehydrogenase measured with 3-ketopalmitoyl-CoA as substrate
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Enzyme activities measured in fibroblasts
Number of subjects: 8
Study: 2850904

Group type: EXPERIMENTAL
Intervention: enalapril 10-20 mg/d
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: hydrochlorothiazide (HCTZ) 12.5-25 mg/d
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: combination therapy (enalapril + HCTZ)
Number of subjects: 38

Group type: COMPARATOR
Intervention: HCTZ alone
Number of subjects: 38

Group type: COMPARATOR
Intervention: enalapril + HCTZ
Number of subjects: 38
Study: 30475454

Group type: EXPERIMENTAL
Intervention: High-tech Speech Generating Device (SGD)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Low-tech Picture Exchange Communication System (PECS)
Number of subjects: 35
Study: 27661661

Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow MSCs by intradiscal injection of 25 × 10 cells per segment under local anesthesia
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sham infiltration of paravertebral musculature with anesthetic
Number of subjects: 24
Study: 26312580

Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (800 IU, 2000 IU, 4000 IU)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 71
Study: 23289530

Group type: EXPERIMENTAL
Intervention: 4 fractions of 3.8 Gy (n=60)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: 2 fractions of 7.2 Gy (n=82)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Complete response patients
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Progressive disease patients
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: KPS ≤ 60 at start
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: KPS > 60 at start
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: KPS improvement during therapy
Number of subjects: 142
Study: 21893568

Group type: EXPERIMENTAL
Intervention: Educational intervention (small educational group sessions with nurses and physicians, feedback on prescribing, presentation of guidelines and written materials)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no educational intervention)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 58
Study: 18057912

Group type: EXPERIMENTAL
Intervention: Clo‐Met (100 mg clotrimazole and 100 mg metronidazole)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Clotrimazole (100 mg)
Number of subjects: 165
Study: 16931507

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.25 mg/day
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.50 mg/day
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Pramipexole 0.75 mg/day
Number of subjects: 344

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Pramipexole (all doses combined)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 344
Study: 12656937

Group type: EXPERIMENTAL
Intervention: Daily left prefrontal rTMS (5 Hz, 110% motor threshold, 8 sec on, 22 sec off, over 20 min) for 2 weeks
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Daily left prefrontal rTMS
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 23
Study: 11026517

Group type: EXPERIMENTAL
Intervention: Vitamin E (800 IU/day)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (soybean oil)
Number of subjects: 47
Study: 7773117

Group type: EXPERIMENTAL
Intervention: Current MMT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Previous MMT and non-MMT
Number of subjects: 0

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 0
Study: 2110603

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Cromolyn sodium
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 380367

Group type: EXPERIMENTAL
Intervention: Haloperidol 20-35 mg intravenously
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diazepam 30-40 mg intravenously
Number of subjects: 20
Study: 29872922

Group type: EXPERIMENTAL
Intervention: Chemically interesterified palm olein (IPO)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Palm olein (PO)
Number of subjects: 21

Group type: COMPARATOR
Intervention: High oleic sunflower oil (HOS)
Number of subjects: 21
Study: 29029049

Group type: EXPERIMENTAL
Intervention: High-remifentanil with naloxone (4 ng ml-1 remifentanil with 0.05 μg kg-1 h-1 naloxone)
Number of subjects: 91

Group type: COMPARATOR
Intervention: High-remifentanil (4 ng ml-1 remifentanil)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Low-remifentanil (1 ng ml-1 remifentanil)
Number of subjects: 91

Group type: COMPARATOR
Intervention: High-remifentanil
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: High-remifentanil with naloxone
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Low-remifentanil
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 91
Study: 26371617

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT) plus treatment-as-usual (TAU)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral analysis system of psychotherapy (CBASP) plus treatment-as-usual (TAU)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 106
Study: 23591273

Group type: EXPERIMENTAL
Intervention: Numeric literacy (Asthma Numeracy Questionnaire)
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Print literacy (Short Test of Functional Health Literacy in Adults)
Number of subjects: 284
Study: 21210958

Group type: EXPERIMENTAL
Intervention: Intimacy-Enhancing Therapy (IET)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 71
Study: 19490594

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 6000

Group type: COMPARATOR
Intervention: Intermediate target range for blood glucose
Number of subjects: 6000
Study: 16760445

Group type: EXPERIMENTAL
Intervention: Azithromycin (1 g single dose)
Number of subjects: 195

Group type: COMPARATOR
Intervention: Ciprofloxacin (1 g single dose)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 195

Group type: COMPARATOR
Intervention: Ciprofloxacin
Number of subjects: 195
Study: 14757848

Group type: EXPERIMENTAL
Intervention: BQ-123 (60 microg/min for 30 min) during placebo clamp conditions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BQ-123 (60 microg/min for 30 min) during euglycemic hyperinsulinemia (3 mU/kg/min for 390 min)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo during euglycemic hyperinsulinemia
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BQ-123 (32 microg/min for 120 min) during placebo or insulin clamp
Number of subjects: 20
Study: 11211371

Group type: EXPERIMENTAL
Intervention: Fluvoxamine 50 to 200 mg/day
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Number of subjects: 120
Study: 9559411

Group type: EXPERIMENTAL
Intervention: Adenosine (140 micrograms/kg per min)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dobutamine (20 micrograms/kg per min)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 16
Study: 7862784

Group type: EXPERIMENTAL
Intervention: MMPI
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Millon
Number of subjects: 133
Study: 2656623

Group type: EXPERIMENTAL
Intervention: Cefmetazole (2 g intra-operative iv dose)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Cefotetan (2 g intra-operative iv dose)
Number of subjects: 36
Study: 4943034

Group type: EXPERIMENTAL
Intervention: Penfluridol 30 mg weekly oral dose
Number of subjects: 30
Study: 30508094

Group type: EXPERIMENTAL
Intervention: Diet fortified with a Zn AA complex (2 × NRC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Diet fortified with ZnSO4 (2 × NRC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control diet without fortified Zn (1 × NRC)
Number of subjects: 16
Study: 28645191

Group type: EXPERIMENTAL
Intervention: ALGO DE (n=91)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: ALGO SW (n=89)
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: ALGO LA (n=86)
Number of subjects: 440

Group type: COMPARATOR
Intervention: TAU (n=84)
Number of subjects: 440

Group type: COMPARATOR
Intervention: CDES (n=79)
Number of subjects: 440
Study: 25982053

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 39

Group type: COMPARATOR
Intervention: CsA
Number of subjects: 39
Study: 23690582

Group type: EXPERIMENTAL
Intervention: B-vitamin treatment (folic acid 0.8 mg, vitamin B6 20 mg, vitamin B12 0.5 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B-vitamin treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 0
Study: 21486960

Group type: EXPERIMENTAL
Intervention: TBR-652 (25, 50, 75, 100, and 150 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 19909421

Group type: EXPERIMENTAL
Intervention: COPE (Creating Opportunities for Personal Empowerment) Healthy Lifestyles TEEN program
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: COPE program (subset of 7 overweight adolescents)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Attention control program
Number of subjects: 19
Study: 16977280

Group type: EXPERIMENTAL
Intervention: Gardasil (recombinant quadrivalent human‐papillomavirus‐like particle vaccine)
Number of subjects: 0
Study: 12757345

Group type: EXPERIMENTAL
Intervention: Single aortic clamp (SAC)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Partial occluding clamp (POC)
Number of subjects: 268
Study: 10883664

Group type: EXPERIMENTAL
Intervention: IdUrd
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Cyclin A
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Ki‐67
Number of subjects: 65
Study: 9339548

Group type: EXPERIMENTAL
Intervention: Corn peptide (CP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Wheat peptide (WP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Alanine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Leucine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Pea peptide (PP)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no peptide)
Number of subjects: 10
Study: 8245265

Group type: EXPERIMENTAL
Intervention: Cryopreserved cultured epidermal allografts (CCAs)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Hydrocolloid dressings (HCDs)
Number of subjects: 43
Study: 4050315

Group type: EXPERIMENTAL
Intervention: Paralgin forte
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Positive instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative instructions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neutral instructions
Number of subjects: 0
Study: 30464407

Group type: EXPERIMENTAL
Intervention: Fasted condition (entecavir administration)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Fed condition (entecavir administration)
Number of subjects: 96
Study: 27071819

Group type: EXPERIMENTAL
Intervention: Overweight (BMI 25 to <30 kg/m2)
Number of subjects: 17913

Group type: EXPERIMENTAL
Intervention: Obese (BMI ≥30 kg/m2)
Number of subjects: 17913

Group type: EXPERIMENTAL
Intervention: High waist circumference (WC) in women
Number of subjects: 17913
Study: 25390467

Group type: EXPERIMENTAL
Intervention: Early palliative care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinician roles in early palliative care
Number of subjects: 0
Study: 20231857

Group type: EXPERIMENTAL
Intervention: Nicotine (4 mg as gum)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 19695099

Group type: EXPERIMENTAL
Intervention: NT-pro BNP monitoring
Number of subjects: 42

Group type: COMPARATOR
Intervention: NT-pro BNP levels
Number of subjects: 42
Study: 17669629

Group type: EXPERIMENTAL
Intervention: NET+VOC
Number of subjects: 72

Group type: COMPARATOR
Intervention: VOC
Number of subjects: 72
Study: 15136963

Group type: EXPERIMENTAL
Intervention: Acupressure with massage for 12 minutes per day, three days per week, for four weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Routine unit care (Control)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Acupressure with massage
Number of subjects: 62
Study: 11157665

Group type: EXPERIMENTAL
Intervention: Nitric oxide synthesis inhibitor N:(G)monomethyl‐L‐arginine (5.3+/‐1.2%)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged episodes of reactive hyperemia, hand warming, or incremental infusion of acetylcholine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transient hyperemia
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sustained hyperemia
Number of subjects: 0
Study: 9128028

Group type: EXPERIMENTAL
Intervention: Epidural clonidine 150 micrograms before incision
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Oral clonidine 150 micrograms 60-90 min prior to arrival in the operating room
Number of subjects: 159

Group type: COMPARATOR
Intervention: Control group (no clonidine)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 159
Study: 7966500

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0
Study: 3295020

Group type: EXPERIMENTAL
Intervention: Lactitol (66.7 g/100 ml)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Lactulose (66.7 ml (44.5 g)/100 ml)
Number of subjects: 9
Study: 41550

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 10